VEGFA and age-related macular degeneration: As such, therapies in the form of angiogenic inhibitors, including those acting against the bioactivity of vascular endothelial growth factor (VEGF), have been the mainstay of AMD treatment [20]; however, because VEGF is also a neuroprotective agent [21] and a survival factor for endothelial cells [22], inhibiting its bioactivity may not only inhibit CNV, but also reduce these beneficial properties of VEGF.